Literature DB >> 11371682

Viral load differences in early infection with two HIV-1 subtypes.

D J Hu1, S Vanichseni, T D Mastro, S Raktham, N L Young, P A Mock, S Subbarao, B S Parekh, L Srisuwanvilai , R Sutthent, C Wasi, W Heneine, K Choopanya.   

Abstract

OBJECTIVES: Information on early HIV-1 infection has come primarily from studies of persons infected with subtype B in North America and Europe; much less is known about other subtypes. The purpose of the present study was to compare the virologic and immunologic parameters following seroconversion among recently-infected persons infected with either of two different HIV-1 subtypes.
METHOD: A prospective cohort study was carried out at methadone treatment clinics administered by the Bangkok Metropolitan Administration, Thailand. A total of 130 HIV-1-infected seroconverters (103 with HIV-1 subtype E and 27 with subtype B) were included in the study. The main outcome measures were serial HIV-1 RNA viral load, natural killer cell percentage, CD4 and CD8 lymphocyte counts since seroconversion.
RESULTS: The demographic and behavioral characteristics of persons with either subtype were similar. Median RNA viral levels at the earliest time within 3 months of seroconversion were more than three times higher for persons infected with subtype E than subtype B (63 100 versus 18 050 copies/ml, P = 0.001). However, this difference decreased over time such that viral loads were similar at 12, 18, and 24 months following seroconversion. The CD4 and CD8 lymphocyte counts were similar in infections with either subtype during the entire period up to 24 months post-seroconversion.
CONCLUSIONS: Higher viral loads associated with subtype E may result from inter-subtype biological differences; however, the epidemiological dynamics of transmission in Bangkok may have also contributed to this phenomenon.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371682     DOI: 10.1097/00002030-200104130-00003

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  30 in total

1.  Viral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission.

Authors:  Philip L Bulterys; Sudeb C Dalai; David A Katzenstein
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

Review 2.  T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.

Authors:  Bette T Korber; Norman L Letvin; Barton F Haynes
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

Review 3.  The challenge of HIV-1 subtype diversity.

Authors:  Barbara S Taylor; Magdalena E Sobieszczyk; Francine E McCutchan; Scott M Hammer
Journal:  N Engl J Med       Date:  2008-04-10       Impact factor: 91.245

4.  Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

Authors:  Philippa J Easterbrook; Mel Smith; Jane Mullen; Siobhan O'Shea; Ian Chrystie; Annemiek de Ruiter; Iain D Tatt; Anna Maria Geretti; Mark Zuckerman
Journal:  J Int AIDS Soc       Date:  2010-02-03       Impact factor: 5.396

5.  Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses.

Authors:  Jérémie Prévost; Daria Zoubchenok; Jonathan Richard; Maxime Veillette; Beatriz Pacheco; Mathieu Coutu; Nathalie Brassard; Matthew S Parsons; Kiat Ruxrungtham; Torsak Bunupuradah; Sodsai Tovanabutra; Kwan-Ki Hwang; M Anthony Moody; Barton F Haynes; Mattia Bonsignori; Joseph Sodroski; Daniel E Kaufmann; George M Shaw; Agnès L Chenine; Andrés Finzi
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

6.  Molecular epidemiology of human immunodeficiency virus type 1 sub-subtype A3 in Senegal from 1988 to 2001.

Authors:  Seema Thakore Meloni; Jean-Louis Sankalé; Donald J Hamel; Geoffrey Eisen; Aissatou Guéye-Ndiaye; Souleymane Mboup; Phyllis J Kanki
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  CDC international HIV prevention research activities among injection drug users in Thailand and Russia.

Authors:  Alan E Greenberg; Jordan Tappero; Kachit Choopanya; Frits van Griensven; Mike Martin; Suphak Vanichseni; Scott Santibanez; Valerie Molotilov; Shannon Hader; Laura N Broyles
Journal:  J Urban Health       Date:  2005-09       Impact factor: 3.671

8.  The human immunodeficiency virus type 1 promoter contains a CATA box instead of a TATA box for optimal transcription and replication.

Authors:  Tim van Opijnen; Joost Kamoschinski; Rienk E Jeeninga; Ben Berkhout
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users.

Authors:  Artur Ramos; Dale J Hu; Lily Nguyen; Kim-Oanh Phan; Suphak Vanichseni; Nattawan Promadej; Kachit Choopanya; Margaret Callahan; Nancy L Young; Janet McNicholl; Timothy D Mastro; Thomas M Folks; Shambavi Subbarao
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Rapid detection of human immunodeficiency virus type 1 subtype e infection by PCR.

Authors:  Mao-Yuan Chen; Wei-Kung Wang; Ming-Cheng Lee; Shing-Jer Twu; Shiow-Ing Wu; Chun-Nan Lee
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.